These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 8953454)
1. Immunoglobulins and complement deposits in mitroflow pericardial bioprosthetic heart valves--a contributing factor to structural deterioration. Moczar M; Lecerf L; Mazzucotelli JP; Loisance D J Heart Valve Dis; 1996 Nov; 5 Suppl 3():S276-83. PubMed ID: 8953454 [TBL] [Abstract][Full Text] [Related]
2. Complement activation is involved in the structural deterioration of bovine pericardial bioprosthetic heart valves. Moczar M; Lecerf L; Ginat M; Loisance D ASAIO J; 1996; 42(5):M375-81. PubMed ID: 8944911 [TBL] [Abstract][Full Text] [Related]
3. Structural changes in porcine bioprosthetic valves of a left ventricular assist system in human patients. Moczar M; Houël R; Ginat M; Clérin V; Wheeldon D; Loisance D J Heart Valve Dis; 2000 Jan; 9(1):88-95; discussion 95-6. PubMed ID: 10678380 [TBL] [Abstract][Full Text] [Related]
4. Different modes of degeneration in autologous and heterologous heart valve prostheses. Grabenwöger M; Fitzal F; Gross C; Hutschala D; Böck P; Brucke P; Wolner E J Heart Valve Dis; 2000 Jan; 9(1):104-9; discussion 110-1. PubMed ID: 10678382 [TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of the MitroFlow pericardial bioprosthesis in the elderly after aortic valve replacement. Sjögren J; Gudbjartsson T; Thulin LI J Heart Valve Dis; 2006 Mar; 15(2):197-202. PubMed ID: 16607900 [TBL] [Abstract][Full Text] [Related]
13. Structural deterioration of the Freestyle aortic valve: mode of presentation and mechanisms. Mohammadi S; Baillot R; Voisine P; Mathieu P; Dagenais F J Thorac Cardiovasc Surg; 2006 Aug; 132(2):401-6. PubMed ID: 16872969 [TBL] [Abstract][Full Text] [Related]
14. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement. Yeghiazaryan K; Skowasch D; Bauriedel G; Schild H; Golubnitschaja O Amino Acids; 2007 Jan; 32(1):109-14. PubMed ID: 16874466 [TBL] [Abstract][Full Text] [Related]
15. Left ventricular mass regression after aortic valve replacement with the new Mitroflow 12A pericardial bioprosthesis. García-Bengochea J; Sierra J; González-Juanatey JR; Rubio J; Vega M; Fernández AL; Sánchez D J Heart Valve Dis; 2006 May; 15(3):446-51; discussion 451-2. PubMed ID: 16784087 [TBL] [Abstract][Full Text] [Related]
16. Lack of durability of the Mitroflow valve does not affect survival. Houel R; Le Besnerais P; Soustelle C; Kirsch M; Hillion ML; Loisance D J Heart Valve Dis; 1999 Jul; 8(4):368-74; discussion 374-5. PubMed ID: 10461235 [TBL] [Abstract][Full Text] [Related]
18. Lipid-mediated inflammation and degeneration of bioprosthetic heart valves. Shetty R; Pibarot P; Audet A; Janvier R; Dagenais F; Perron J; Couture C; Voisine P; Després JP; Mathieu P Eur J Clin Invest; 2009 Jun; 39(6):471-80. PubMed ID: 19490057 [TBL] [Abstract][Full Text] [Related]
19. A new model to test the calcification characteristics of bioprosthetic heart valves. Ozaki S; Herijgers P; Flameng W Ann Thorac Cardiovasc Surg; 2004 Feb; 10(1):23-8. PubMed ID: 15008695 [TBL] [Abstract][Full Text] [Related]